China Leads Asia-Pacific's Rise as a Global Clinical Trial Hub
核心洞察
Asia-Pacific is solidifying its position as a key region for clinical trials, driven significantly by activity in China.
China accounted for 39% of all clinical trial starts in the Asia-Pacific region in 2023, demonstrating its dominance.
The Citeline (搜索) White Paper highlights China's increasing global importance in clinical trial activity.
Asia-Pacific is increasingly becoming a pivotal region for clinical trials, with China leading the way in this expansion. According to a new Citeline (搜索) White Paper, China accounted for 39% of all clinical trial starts in the APAC region in 2023, underscoring its dominance in the area.
China's Growing Influence
The Citeline (搜索) White Paper highlights China's increasing role in global clinical trial activity. This surge is attributed to several factors, including a large patient population, streamlined regulatory processes, and growing investment in healthcare infrastructure.
APAC's Emergence
The broader Asia-Pacific region is also experiencing growth in clinical trial activity. This growth is driven by increasing healthcare expenditure, a rising prevalence of chronic diseases, and a growing number of skilled healthcare professionals. The region's diverse population also provides opportunities for conducting trials across various ethnic groups, enhancing the generalizability of trial results.